On May 6, Pfizer appointed a former Citigroup executive as its chief strategy and innovation officer, executive vice president.
Andrew Baum, MD, has served as the head of global healthcare and managing director of equity research at Citi, where he's been working since 2011. In June, he will join Pfizer and succeed Aamir Malik, who recently became the drugmaker's chief U.S. commercial officer, executive vice president.
In his new role, Dr. Baum will lead Pfizer's portfolio management team, the company said in a news release.
Before Citi, Dr. Baum covered European Pharmaceuticals at Morgan Stanley for 14 years; prior to that role, he was a physician.